Tickers

1. Composite Trajectory Verdict

All three statements carry roughly equal weight because MBLY is a high-R&D semiconductor company with significant goodwill, where revenue growth, cash generation, and balance sheet resilience are all critical to assessing trajectory.

Composite Trajectory: Mixed

Annual revenue fell 20% to $1,654 million in FY2024 then rose 15% to $1,894 million in FY2025, still 9% below FY2023's $2,079 million (10-K FY2025, Statement of Operations). Gross margin improved from 45% to 48% but remains below FY2023's 50% (10-K FY2025, Statement of Operations). Operating loss narrowed from -$3,225 million (including $2,695 million goodwill impairment) in FY2024 to -$440 million in FY2025; excluding impairments, operating loss improved from -$530 million to -$440 million (10-K FY2025, Statement of Operations). Operating cash flow increased annually from $394 million to $602 million (10-K FY2025, Statement of Cash Flows), but declined 35% YoY in H1 2026 to $210 million (10-Q H1 2026, Statement of Cash Flows). Cash balance grew from $1,438 million to $1,860 million (10-K FY2025, Balance Sheet), while equity declined from $12,087 million to $11,881 million and liabilities rose 24% (10-K FY2025, Balance Sheet). Two large goodwill impairments ($2,695 million in FY2024, $3,788 million in H1 2026) signal valuation pressure (10-K FY2025, Note 10; 10-Q H1 2026, MD&A). These conflicting signals yield a mixed trajectory.

2. Red Flags

• Goodwill impairment of $2,695 million in FY2024 and $3,788 million in H1 2026 (10-K FY2025, Note 10; 10-Q H1 2026, MD&A).
• GAAP net loss of $392 million in FY2025 vs positive operating cash flow of $602 million (10-K FY2025, Statement of Operations; 10-K FY2025, Statement of Cash Flows).
• Share-based compensation expense rising: $252M (FY2023), $279M (FY2024), $277M (FY2025); $134M in H1 2025 vs $172M in H1 2026 (10-K FY2025, Note 6; 10-Q H1 2026, MD&A).
• Customer concentration: Customer A represented 30% of FY2025 revenue and 39% of year-end receivables (10-K FY2025, Note 12).
• Sole-source dependency on STMicroelectronics for EyeQ SoCs (10-K FY2025, MD&A; 10-K FY2025, Note 14).
• Valuation allowance of $955 million on deferred tax assets as of FY2025, primarily U.S. branch losses (10-K FY2025, Note 8).
• Related-party acquisition of Mentee Robotics for $900 million (cash and stock) where CEO and CTO are founders (10-K FY2025, Note 1; 10-K FY2025, Note 15).
• Goodwill impairment sensitivity: 1% discount rate increase triggers ~$834 million impairment (10-K FY2025, Note 10).
• Pending appeal of dismissed class action (10-K FY2025, Note 14).

3. Earnings Assessment

Earnings Trajectory: Mixed

Overall Assessment: Annual revenue fell 20% to $1,654 million in FY2024 then rose 15% to $1,894 million in FY2025, still 9% below FY2023's $2,079 million (10-K FY2025, Statement of Operations). Gross margin improved from 45% to 48% but remains below FY2023's 50% (10-K FY2025, Statement of Operations). Operating loss narrowed from -$3,225 million (including $2,695 million goodwill impairment) in FY2024 to -$440 million in FY2025; excluding impairments, operating loss improved from -$530 million to -$440 million (10-K FY2025, Statement of Operations). R&D expense rose each year: $889M, $1,083M, $1,151M (10-K FY2025, Statement of Operations). In H1 2026, revenue grew 13% to $1,066 million YoY, but a $3,788 million goodwill impairment drove GAAP operating loss to -$3,926 million vs -$191 million in H1 2025 (10-Q H1 2026, MD&A). Excluding impairment, H1 2026 operating loss would be -$138 million, an improvement. However, the recurring large impairments and rising operating expenses keep the earnings trajectory mixed.

4. Cash Generation Assessment

Cash Trajectory: Mixed

Overall Assessment: Annual operating cash flow increased steadily: $394 million (FY2023), $400 million (FY2024), $602 million (FY2025) (10-K FY2025, Statement of Cash Flows). Investing outflows were stable near -$100 million annually. Financing outflows included a $100 million share repurchase in FY2025. Cash balance grew from $1,226 million to $1,860 million over three years (10-K FY2025, Statement of Cash Flows). However, in H1 2026, operating cash flow declined 35% to $210 million from $322 million in H1 2025, while investing cash outflow surged to -$719 million (including $591 million for Mentee acquisition) from -$39 million (10-Q H1 2026, Statement of Cash Flows). Financing outflow was $24 million for share repurchases. The annual trend shows improving cash generation, but the most recent semi-annual period shows significant deterioration due to acquisition-related outflows, resulting in a mixed cash trajectory.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Overall Assessment: Total assets were nearly flat: $12,579 million (FY2024) vs $12,492 million (FY2025) (10-K FY2025, Balance Sheet). Cash and equivalents rose 30% from $1,438 million to $1,860 million, while inventories fell 21% ($415M to $327M) and receivables fell 38% ($212M to $131M) (10-K FY2025, Balance Sheet). Total liabilities increased 24% from $492 million to $611 million, driven by higher accrued expenses ($190M to $228M), long-term employee benefits ($62M to $78M), deferred tax liabilities ($47M to $60M), and lease liabilities ($50M to $62M) (10-K FY2025, Balance Sheet). Equity declined from $12,087 million to $11,881 million due to net loss and $100 million share repurchase (10-K FY2025, Statement of Changes in Equity). Goodwill remained at $8,200 million with no annual impairment in FY2025, but a $3,788 million impairment occurred in H1 2026 (10-K FY2025, Note 10; 10-Q H1 2026, MD&A). The balance sheet shows strengthening liquidity but rising obligations and equity erosion, yielding a mixed trajectory.

6. Data Gaps

• Quarterly income statements for Q1 2026, Q3 2025, and Q4 2025 (only annual and H1 2026 provided).
• Balance sheet as of June 27, 2026 (10-Q H1 2026 balance sheet truncated).
• Full segment reporting for Moovit ("Other" segment) revenue and expense breakdown.
• Detailed revenue split between EyeQ SoC and SuperVision for semi-annual periods.
• Cash flow statement for Q2 2026 alone (only six-month provided).
• Impact of R&D Law incentive grant on future R&D expense recognition.
• Terms and valuation of TSMC supply agreement for future EyeQ generations.
• Resolution of pending class action appeal and derivative lawsuits.